Chronic liver disease gets worse when the liver's immune system stays overactive, resulting in ongoing inflammation and ...

CK0804, a regulatory T cell therapy, received FDA orphan drug designation for myelofibrosis, supporting rare disease treatment development. Clinical study results showed significant reductions in ...

Researchers at University College London (UCL) have uncovered a key mechanism that helps the body switch off inflammation – a breakthrough that could ...

Treg therapeutic designed to preferentially traffic towards its ligand CXCL12 over expressed in the bone marrow and spleen in myelofibrosis. -- CK0804 engages with antigen presenting cells within ...

A 200,000-year-old molar from Denisova Cave has provided a glimpse into the life of Denisovans, revealing startling new ...

Retained products of conception (RPOC) is a condition where some remnants of trophoblast or placenta are retained after ...

Novel research led by Brazilian scientists describes the immune system's reactions in detail in the first living patient to ...

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) is trading at three year highs despite market volatility, responding to breakthrough innovations and increased deals involving NASDAQ biotech stocks.

Pioneering research led by Brazilians describes the immune system's reactions in detail in the first living patient to receive a genetically modified pig kidney transplant.

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with ...

Researchers from Austria have discovered that fructose, the sugar found in fruit and sweetened drinks, can heighten inflammation in the body, potentially influencing how we respond to infections.